Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Urologic Oncology: Seminars and Original Investigations is Scopus-indexed (Q2, CiteScore 4.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 1078-1439Verify ISSN ↗1873-2496Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: About US$3,440 to publish open access (publisher list price, via OpenAlex) — subscription publishing may be free
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Urology | 32 / 123 | 74th | Q2 |
| Oncology | 182 / 428 | 57th | Q2 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1995–present, best quartile Q2, CiteScore 4.6.
Urologic Oncology: Seminars and Original Investigations is Q2 in Urology (rank 32 of 123) and Q2 in Oncology (rank 182 of 428), by CiteScore 2025.
Urologic Oncology: Seminars and Original Investigations is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.6, which places it in quartile Q2 at the 74th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.997, quartile Q1, with an H-index of 93.
The publisher lists an article processing charge of about US$3,440 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Urologic Oncology: Seminars and Original Investigations is published by Elsevier Inc. Its print ISSN is 1078-1439 and its online ISSN is 1873-2496.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Urologic Oncology: Seminars and Original Investigations has an h-index of 108 and a 2-year mean of 1.43 citations per paper (OpenAlex). Its Scopus CiteScore is 4.6, quartile Q2. On 2-year citations it ranks #53 of 123 Scopus journals in Urology.
Urologic Oncology: Seminars and Original Investigations published 613 papers in 2025. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 94 research articles (2026), authors are most often from United States (41.2%), China (14.5%) and Japan (9.9%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 9 retracted papers are recorded (1.2 per 1,000 papers). The Problematic Paper Screener flags 1 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.